azeliragon (TTP488) / Cantex Pharma, vTv Therapeutics  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
azeliragon (TTP488) / Cantex Pharma
2017-004065-27: Clinical Study to assess the Safety And Efficacy Of Investigational Medicinal Product Azeliragon (TTP488) In Patients With Mild Alzheimer's Disease who have previously completed a Clinical Trial with Azeliragon (TP488)

Not yet recruiting
3
800
Europe
Azeliragon, TTP488, Capsule, hard
vTv THERAPEUTICS LLC, vTv THERAPEUTICS LLC
MILD ALZHEIMER'S DISEASE, MILD ALZHEIMER'S DISEASE, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05815485: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

Recruiting
2/3
144
US
Azeliragon, Placebo
Salim S. Hayek
COVID-19
04/26
04/26

Download Options